The Department of Justice has asked the Supreme Court to allow the Corporate Transparency Act (CTA) to move forward after conflicting court rulings paused, unpaused and then blocked its enforcement.

RBC Capital analyst Luca Issi maintained a Hold rating on Moderna (MRNA – Research Report) on January 13 and set a price target of $40.00. The company’s shares closed yesterday at $34.77.

In a report released today, Terence Flynn from Morgan Stanley assigned a Hold rating on Moderna (MRNA – Research Report), with a price target of $38.00. Discover outperforming stocks and invest ...

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial ...

The company also delayed its break-even timeline from 2026 to 2028. View of Moderna company office entrance exterior with logo sign in Cambridge, Massachusetts, June 14, 2024. Shares fell 19 ...

Shares plunge more than 24% in early trading 2025 revenue forecast misses expectations, prior view CEO Bancel says to reduce 2025 cash costs by $1 bln Jan 13 (Reuters) - Moderna (MRNA.O), opens ...

Moderna cut its 2025 sales forecast by $1 billion today, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines, sending its shares down more ...

Moderna's partnership with Merck in personalized cancer therapies and promising Phase III trials support a speculative 'Buy' for long-term investors with high-risk tolerance. Despite a tough 2024 ...

In this article, we are going to take a look at where Moderna Inc. (NASDAQ:MRNA) stands against other firms end 2024 stronger with impressive gains. A lackluster trading persisted throughout the ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins Some states have laws and ethical rules regarding solicitation and ...